new endpoints for multiple orphan indications are being defined in this lecture

Inflammation in the Inflammatory bowel diseases may be driven by diet , as evidenced to date by the return of inflammation in patients transitioning from exclusive enteral nutrition to partial enteral nutrition. Exclusion diets such as the Crohn’s disease exclusion diets cause a decrease in inflammation and mucosal healing in Crohn’s disease. These findings suggest that certain dietary components may be one of the culprits in driving the surge of IBD around the globe. One of the key suspects are dietary additives.
In the current talk we will review the effects of dietary additives such as:
maltodextrins
carrageenans
 gums
emulsifiers
and the effects upon the microbiome and goblet cells.

Elucidate factors that help to make the successful transition from the bench to research group leader.

Understand the clinical features of IBD
Recognise the endoscopic findings in IBD
Review the potential treatments for IBD

1. To understand the objectives and necessity of head to head trials of new targeted therapies against active comparators in IBD

2. To understand the types of head to head trials in IBD

3. To follow the details of completed head to head trials in IBD and their conclusions

4. To interpret recently completed head to head trials in IBD 

Hot topics list (2020-2021)
1.Disease mechanisms
2.(Differential) diagnoses
3.COVID-19
4.Endoscopy scoring
5.Histology
6.Clinical trials involving histology
7.IBD-associated neoplasia

1. To address the importance of developing high-quality guidelines
2. To address some of the issues behind guideline quality variability
3. To discuss the different domains that dictate standards of quality in guidelines

We will review the following items with respect to IBD:
1. History & epidemiology
2. pathogenesis 
3. genetics
4. environmental factors

Educational objectives: 

1. To emphasise the role of investigator-initiated studies compared to phase 3 randomized controlled trials in assessing the safety profile of IBD related treatments
2. To review the definition of real world data and the different types of real world data
3. To provide examples on investigator-initiated cohorts assessing the safety profile of IBD related treatments
4. To have an overview of the main administrative health databases used in the assessment of the safety profile of IBD related treatment

Aims of this talk are to:

     - Introduce the concepts of machine learning
     - Relay how machine learning is currently being applied in the filed of IBD
     - Present some applications using 'Omics data
     - Suggest how advancing applications might relate to treatment in IBD

To review how to manage resources when writing GRADE guidelines
To review the pros and cons of universal guidelines

1. appropriate assessment
2. risk factors

 In this talk we will discuss simple yet often overlooked pearls and tips to get the most of old-school medications, focusing on thiopurines and 5ASA. We will examine which combination of topical and oral 5ASA is best in each clinical scenario, discuss the role of compliance, how to optimize technical aspects of rectal agents, desensitization and factors not to be overlooked which may contribute to recalcitrant IBD. We will also explore metabolite testing for thiopurines in clinical practice and the evidence backing its use for maintenance monotherapy 

1. anti-integrins
2. p19/p40 inhibitors
3. JAK inhibitors
4. positioning biologics
5. small molecules

1. To understand proper timing of surgical indication in abdominal Crohn's disease
2. To outline that delay in surgery leads to worse outcomes
3. To delineate surgical indication in perianal CD in two phases (as adjunctive to initiation of biologics and with additional procedures if persistence of fistulas after mucosal healing of the rectum)
4. To detail proper timing of surgery in acute and chronic UC